Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | CLO & Corp. Secretary | January 29, 2022 | February 01, 2022 |
| uniQure N.V.QURE · Entity 4162 | General Counsel | January 27, 2017 | February 21, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rubius Therapeutics, Inc.
Report date January 29, 2022 · Filed February 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,343 |
Ending reported balance
After 2022-02-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-01-29 · Exercise / conversion · Acquired 8,075 · Balance 8,075 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2022-02-01 · Sale · Disposed 2,732 · Balance 5,343 F2: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.71, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 24,225 |
Reported balance
After 2022-01-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-01-29 · Exercise / conversion · Disposed 8,075 · Balance 24,225 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 34,500 |
Reported balance
After 2022-01-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-01-31 · Grant · Acquired 34,500 · Balance 34,500 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.75 · Expires 2032-01-30 | Direct | 143,750 |
Reported balance
After 2022-01-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-01-31 · Grant · Acquired 143,750 · Balance 143,750 F5: 25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.71, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022.
F5: 25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter.
F6: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.
uniQure N.V.
Report date January 27, 2017 · Filed February 21, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.37 · Expires 2027-01-27 | Direct | 43,000 |
Reported balance
After 2017-01-27 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-01-27 · Grant · Acquired 43,000 · Balance 43,000 F4: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F1: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. |
| Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 43,500 |
Reported balance
After 2017-01-27 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2017-01-27 · Grant · Acquired 43,500 · Balance 43,500 F4: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F2: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3: Expiration date is not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested.
F2: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020.
F3: Expiration date is not applicable.
F4: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mural Oncology plc
Report date December 05, 2025 · Filed December 05, 2025
Section 16 reporting ended · disclosed 2025-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 1
1 source rowRow 1 · 2025-12-05 · Disposition to issuer · Disposed 68,834 · Balance 0 F1: Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time"). F2: Includes the disposition of 62,203 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2033-12-13 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-05 · Disposition to issuer · Disposed 54,242 · Balance 0 F3: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.39 · Expires 2034-02-28 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-05 · Disposition to issuer · Disposed 31,200 · Balance 0 F3: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2035-03-02 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-05 · Disposition to issuer · Disposed 65,000 · Balance 0 F3: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time").
F2: Includes the disposition of 62,203 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration.
F3: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2025 Filed Dec 5, 2025 08:52 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerStock Option (right to buy) · Derivative | 65,000 | Not disclosed Strike: $3.43 | Not disclosed |
DisclosureSEC source: 0001193125-25-308760 · ownership.xml · derivative · entry 4 Keson-Brookes Maiken · CIK 0001693805 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 65,000 shares Expires 2035-03-02 F3 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F3 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 08:52 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerStock Option (right to buy) · Derivative | 31,200 | Not disclosed Strike: $5.39 | Not disclosed |
DisclosureSEC source: 0001193125-25-308760 · ownership.xml · derivative · entry 3 Keson-Brookes Maiken · CIK 0001693805 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 31,200 shares Expires 2034-02-28 F3 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F3 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 08:52 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerStock Option (right to buy) · Derivative | 54,242 | Not disclosed Strike: $3.61 | Not disclosed |
DisclosureSEC source: 0001193125-25-308760 · ownership.xml · derivative · entry 2 Keson-Brookes Maiken · CIK 0001693805 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 54,242 shares Expires 2033-12-13 F3 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F3 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 08:52 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerOrdinary Shares | 68,834 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-308760 · ownership.xml · nonDerivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time"). F2 · shares: Includes the disposition of 62,203 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration. F1 · price: Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time"). F2 · price: Includes the disposition of 62,203 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration. Read SEC document |
| July 22, 2025 Filed Jul 23, 2025 17:00 UTC | Mural Oncology plc MURA · Entity 72153 | SaleOrdinary Shares | 2,572 | $2.48 | $6,378.56 |
DisclosureSEC source: 0000950170-25-097949 · ownership.xml · nonDerivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,834 F1 · kind: Represents shares automatically sold by the Reporting Person pursuant to a Rule 10b5-1 trading arrangement that was entered into by the Reporting Person on September 20, 2024. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.46 to $2.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 62,203 unvested restricted stock units. Read SEC document |
| July 18, 2025 Filed Jul 22, 2025 17:00 UTC | Mural Oncology plc MURA · Entity 72153 | SaleOrdinary Shares | 2,158 | $2.48 | $5,351.84 |
DisclosureSEC source: 0000950170-25-097599 · ownership.xml · nonDerivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,406 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 14, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on December 22, 2023, and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 62,203 unvested restricted stock units. Read SEC document |
| March 05, 2025 Filed Mar 5, 2025 16:49 UTC | Mural Oncology plc MURA · Entity 72153 | SaleOrdinary Shares | 1,469 | $3.45 | $5,068.05 |
DisclosureSEC source: 0000950170-25-033769 · ownership.xml · nonDerivative · entry 3 Keson-Brookes Maiken · CIK 0001693805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,564 F5 · kind: Represents shares automatically sold by the Reporting Person pursuant to a Rule 10b5-1 trading arrangement that was entered into by the Reporting Person on September 20, 2024. F2 · balance_after: Includes 34,505 unvested restricted stock units Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 16:49 UTC | Mural Oncology plc MURA · Entity 72153 | SaleOrdinary Shares | 1,262 | $3.36 | $4,240.32 |
DisclosureSEC source: 0000950170-25-033769 · ownership.xml · nonDerivative · entry 2 Keson-Brookes Maiken · CIK 0001693805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,033 F3 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 1, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on December 22, 2023, and the sale does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.36. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 34,505 unvested restricted stock units Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 16:49 UTC | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0000950170-25-033769 · ownership.xml · derivative · entry 4 Keson-Brookes Maiken · CIK 0001693805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,000 Underlying: Ordinary Shares · 65,000 shares Expires 2035-03-02 F6 · derivative.exercise_date: This option was granted on March 3, 2025. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 1, 2026 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued services with the Issuer. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 16:49 UTC | Mural Oncology plc MURA · Entity 72153 | GrantOrdinary Shares | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-033769 · ownership.xml · nonDerivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,295 F1 · shares: Consists of ordinary shares issuable under 35,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 1, 2025, subject to the reporting person's continued service with the Issuer. F2 · balance_after: Includes 34,505 unvested restricted stock units Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 16:02 UTC | Mural Oncology plc MURA · Entity 72153 | SaleOrdinary Shares | 2,555 | $3.27 | $8,354.85 |
DisclosureSEC source: 0000950170-24-140393 · ownership.xml · nonDerivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,295 F1 · kind: Represents shares automatically sold by the Reporting Person pursuant to a Rule 10b5-1 trading arrangement that was entered into by the Reporting Person on September 20, 2024. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.24 to $3.33. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 38,705 unvested restricted stock units. Read SEC document |
| July 18, 2024 Filed Jul 18, 2024 16:04 UTC | Mural Oncology plc MURA · Entity 72153 | SaleOrdinary Shares | 2,157 | $3.41 | $7,355.37 |
DisclosureSEC source: 0000950170-24-084569 · ownership.xml · nonDerivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,850 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 14, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on December 22, 2023, and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 38,705 unvested restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 17:18 UTC | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 31,200 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0000950170-24-024913 · ownership.xml · derivative · entry 2 Keson-Brookes Maiken · CIK 0001693805 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,200 Underlying: Ordinary Shares · 31,200 shares Expires 2034-02-28 F2 · derivative.exercise_date: This option was granted on March 1, 2024. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 1, 2025 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 17:18 UTC | Mural Oncology plc MURA · Entity 72153 | GrantOrdinary Shares | 16,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-024913 · ownership.xml · nonDerivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,007 F1 · shares: Consists of ordinary shares issuable under 16,800 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 1, 2024, subject to the reporting person's continued service with the Issuer. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 16:30 UTC | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 54,242 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000950170-23-071106 · ownership.xml · derivative · entry 2 Keson-Brookes Maiken · CIK 0001693805 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,242 Underlying: Ordinary Shares · 54,242 shares Expires 2033-12-13 F2 · derivative.exercise_date: This option was granted on December 14, 2023. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on July 17, 2024 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 16:30 UTC | Mural Oncology plc MURA · Entity 72153 | GrantOrdinary Shares | 29,207 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-071106 · ownership.xml · nonDerivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,207 F1 · shares: Consists of ordinary shares issuable under 29,207 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of July 17, 2023, subject to the reporting person's continued service with the Issuer. Read SEC document |
| February 01, 2022 Filed Feb 1, 2022 21:19 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | SaleCommon Stock | 2,732 | $6.57 | $17,957.44 |
DisclosureSEC source: 0001179110-22-000694 · edgar.xml · nonDerivative · entry 2 Keson-Brookes Maiken · CIK 0001693805 · CLO & Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,343 F2 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.71, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 21:19 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantRestricted Stock Units · Derivative | 34,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000694 · edgar.xml · derivative · entry 5 Keson-Brookes Maiken · CIK 0001693805 · CLO & Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,500 Underlying: Common Stock · 34,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023. F6 · derivative.expiration_date: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 21:19 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 143,750 | $0.00 Strike: $6.75 | $0.00 |
DisclosureSEC source: 0001179110-22-000694 · edgar.xml · derivative · entry 4 Keson-Brookes Maiken · CIK 0001693805 · CLO & Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,750 Underlying: Common Stock · 143,750 shares Expires 2032-01-30 F5 · derivative.exercise_date: 25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 21:19 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionRestricted Stock Units · Derivative | 8,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000694 · edgar.xml · derivative · entry 3 Keson-Brookes Maiken · CIK 0001693805 · CLO & Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,225 Underlying: Common Stock · 8,075 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022. F4 · derivative.expiration_date: The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 21:19 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionCommon Stock | 8,075 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-22-000694 · edgar.xml · nonDerivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · CLO & Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 15, 2021 Filed Mar 15, 2021 20:28 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $7.70 | $0.00 |
DisclosureSEC source: 0001179110-21-003441 · edgar.xml · derivative · entry 3 Keson-Brookes Maiken · CIK 0001693805 · CLO & Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 25,000 shares Expires 2029-11-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option vested on November 18, 2020, then in 12 equal quarterly installments thereafter. Read SEC document |
| March 15, 2021 Filed Mar 15, 2021 20:28 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | SaleCommon Stock | 25,000 | $20.24 | $505,965.00 |
DisclosureSEC source: 0001179110-21-003441 · edgar.xml · nonDerivative · entry 2 Keson-Brookes Maiken · CIK 0001693805 · CLO & Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan, effective January 15, 2020, adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.69, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 15, 2021 Filed Mar 15, 2021 20:28 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionCommon Stock | 25,000 | $7.70 | $192,500.00 |
DisclosureSEC source: 0001179110-21-003441 · edgar.xml · nonDerivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · CLO & Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 20:27 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantRestricted Stock Units · Derivative | 32,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001129 · edgar.xml · derivative · entry 2 Keson-Brookes Maiken · CIK 0001693805 · CLO & Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,300 Underlying: Common Stock · 32,300 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The shares underlying the restricted stock units will vest in four equal annual installments beginning on January 29, 2022. F3 · derivative.expiration_date: The shares underlying the restricted stock units will vest in four equal annual installments beginning on January 29, 2022. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 20:27 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 142,500 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001179110-21-001129 · edgar.xml · derivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · CLO & Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,500 Underlying: Common Stock · 142,500 shares Expires 2031-01-28 F1 · derivative.exercise_date: 25% of this option shall vest on January 29, 2022, then in 12 equal quarterly installments thereafter. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 20:50 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $7.70 | $0.00 |
DisclosureSEC source: 0001104659-19-069692 · a4.xml · derivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · CLO & Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-11-28 F1 · derivative.exercise_date: 25% of this option shall vest on November 18, 2020, then in 12 equal quarterly installments thereafter. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:28 UTC | uniQure N.V. QURE · Entity 4162 | GrantPerformance Share Unit · Derivative | 43,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003727 · doc1.xml · derivative · entry 2 Keson-Brookes Maiken · CIK 0001693805 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Ordinary Shares · 43,250 shares Expires not disclosed F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 15:28 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 43,250 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003727 · doc1.xml · derivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Ordinary Shares · 43,250 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 17:06 UTC Amendment | uniQure N.V. QURE · Entity 4162 | GrantPerformance Share Unit · Derivative | 43,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008381 · doc1.xml · derivative · entry 2 Keson-Brookes Maiken · CIK 0001693805 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Underlying: Ordinary Shares · 43,500 shares Expires not disclosed F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F2 · derivative.exercise_date: Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020. F3 · derivative.expiration_date: Expiration date is not applicable. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
| January 27, 2017 Filed Feb 21, 2017 17:06 UTC Amendment | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-008381 · doc1.xml · derivative · entry 1 Keson-Brookes Maiken · CIK 0001693805 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Ordinary Shares · 43,000 shares Expires 2027-01-27 F4 · shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F1 · derivative.exercise_date: The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested. F4 · derivative.underlying_shares: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. F4 · balance_after: Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.